Cataya and NAGASE Clear Path to Market with Successful 15,000L Demo Production of Sustainable Personal Care Ingredient
Shanghai, China Oct 22, 2025
(Issuewire.com) - Cataya Bio (Shanghai) Co., Ltd. (“Cataya”), a leader in sustainable ingredient innovation and manufacturing using synthetic biology, today announced it has successfully produced a novel personal care ingredient at the 15,000-liter demo scale. This achievement, reached in collaboration with Nagase & Co., Ltd. (“NAGASE”), validates the product’s commercial readiness and paves the way for full-scale market launch.
Cataya received a grant from the SMCST to accelerate the integration of AI with its advanced synthetic biology platform
Shanghai, China Jul 10, 2025
Cataya’s efforts in integrating AI in microbial cell factory design are now supported by the Shanghai Municipal Commission of Science and Technology. The company’s grant proposal - "SynbioNexus: Al-powered microbial cell factory intelligent design and agile validation" - was selected as one of the Commission's Key Technology Research Projects in synthetic biology.
Cataya Received FDA GRAS Status for Its First Human Milk Oligosaccharide Product, 2'-Fucosyllactose
Shanghai, China Jul 10, 2025
Cataya announced that it has received a "No Questions" letter from the U.S. Food and Drug Administration (FDA) regarding its first human milk oligosaccharide (HMO) product, 2'-Fucosyllactose (2'-FL). The letter affirms the FDA's acceptance of Cataya's conclusion that its 2'-FL ingredient is safe and suitable to be used in non-exempt infant formula and various conventional foods.
Cataya Bio was awarded 「Speciality and Innovation」SME in Shanghai
Shanghai, China Feb 01, 2024
Being awarded the "Speciality and Innovation" certification signifies that Cataya Bio's innovative achievements, in-depth explorations and future potential in the field of synthetic biology have been fully affirmed, and it is also a key engine to drive it to a higher level of comprehensive development. In the face of this honour, Cataya Bio is determined to seize this opportunity to continuously improve its independent innovation capability and core competitiveness, and to apply the cutting-edge technology of synthetic biology to create higher-value-added solutions for its global customers, so as to build a new chapter in biotechnology.
Cataya Bio was awarded「Innovative」SME in Shanghai
Shanghai, China Feb 01, 2024
"Innovative SMEs" are defined as outstanding SMEs with strong professionalism, excellent innovation and good growth. The Shanghai Municipal Commission of Economy and Information Technology has organised the award in 2023, aiming to build a system to cultivate high-quality enterprises and help SMEs develop in a high-quality manner. Cataya Bio has won the award for its outstanding performance and innovative spirit in the field of synthetic biology, which demonstrates its industry status and potential for future development.
Cataya Bio Completed 250 Million Series B Financing
Shanghai, China Sep 04, 2023
Co-led by Hengxu Capital and Eight Roads, followed by Hui Rong Capital and Bits x Bites. This significant investment will play a crucial role in enhancing our platform and expediting the scale-up and production of our end products.
Cataya Bio Completed Over 100 Million Series A+ Financing
Shanghai, China Nov 04, 2022
Led by Eight Roads, followed by Sequoia Capital, Source Capital and Bits x Bites. This round of financing will be used to further strength the team, enhance the platform and accelerate pipeline development.
Cataya Bio Completed Over 100 Million Series A Financing
Shanghai, China May 19, 2022
Led by Source Capital, followed by Bits x Bites and Sherpa. This round of financing will be used to expand the team, build the platform and accelerate pipeline development.